Trending Topic

Illustration of the thought processes in the brain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The prevalence of unruptured intracranial aneurysms (IAs) is approximately 3% of the population, with incidence on the rise due to the increased utilization of neuro-imaging for diverse objectives.1,2 The average risk of rupture for unruptured IA is estimated to vary from 0.3% to exceeding 15% per 5 years.3 Ruptured IA is the primary aetiology of […]

Jessica Ailani, EAN 2021: Phase 3b CONQUER Trial Results

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 2nd 2021

It was a great pleasure to meet with Jessica Ailani (MedStar Georgetown, Georgetown University Hospital, Pasquerilla Healthcare Center, Washington, WA, USA) to discuss the impact of galcanezumab on migraine care in the phase 3b CONQUER trial.

The abstract entitled: ‘Total pain burden in patients with treatment-resistant migraine: effects of galcanezumab in the CONQUER Phase 3b trial’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.

Questions:

  1. What has been the impact of galcanezumab on migraine care? (0:15)
  2. What questions remain unanswered about the clinical utility of galcanezumab? (1:43)
  3. Could you briefly summarise the safety and efficacy findings from the CONQUER trial which you presented at the EAN congress? (4:49)
  4. What do you think will be the clinical impact of these findings? (6:08)
  5. Is there a subgroup of patients which were found to be most likely to benefit from galcanezumab? (7:31)

Disclosures: Jessica Ailani has received honoraria for independent consulting from Amgen, Abbvie, Biohaven, Eli Lilly and Company, Lundbeck, Teva, Impel, Satsuma, Theranica, Axsome, Neso, GlaxoSmithKline, Aeon, and Medscape; has ownership of stocks at CtrlM; is part of the Speakers Bureau (Honoraria for promotional speaking) at Allergan/Abbvie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Teva; and provides editorial services (Honoraria) from Current Pain and Headache Reports, Section editor, Unusual Headache Syndromes, NeurologyLive, and SELF (medical reviewer). Jessica Ailani also receives clinical trial grants (Fees to Institution) from American Migraine Foundation, Allergan, Biohaven, Eli Lilly and Company, Satsuma, and Zosano.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch

Filmed as a highlight of the EAN Congress, Virtual 2021

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup